Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06279130 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Study acronym: NEOASIS
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 92 to 133 Interventions: balstilimab (Drug), botensilimab (Drug) to FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) (Drug), balstilimab (Drug), botensilimab (Drug) · Eligibility criteria expanded, about 20 words · Study description expanded, about 59 words · 1 morev3 Show 4 more changesShow less
    • Interventions: balstilimab (Drug), botensilimab (Drug) to FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) (Drug), balstilimab (Drug), botensilimab (Drug)
    • Eligibility criteria expanded, about 20 words
    • Study description expanded, about 59 words
    • Study arms: 8 to 11

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
Trial Details
NCT Number NCT06279130
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Agenus Inc.
Conditions Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
Enrollment 133 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov